Biotech: Page 13
-
Staff shortages cause slowdowns in booming cell and gene therapy market
New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.
By Karissa Waddick • April 3, 2023 -
Opinion
Leaders wave a magic wand at pharma’s thorniest issues
The major challenges pharma leaders would solve with a quick flick of an imaginary wand.
By PharmaVoice staff • March 31, 2023 -
Trendline
Oncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Predator and prey: Harnessing phages to fight antibiotic resistance
Phages, bacteria’s natural predator, could help combat the growing threat of superbugs. But can these therapies rise above antibiotic market woes?
By Karissa Waddick • March 30, 2023 -
Q&A
Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork
Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.
By Michael Gibney • March 30, 2023 -
Seamless clinical trials were created to make studies easier — instead, they’ve become more complex
Experts weigh in on how companies can design better trials that merge two phases into one.
By Meagan Parrish • March 29, 2023 -
Podcast
Woman of the Week: Psilera’s Jackie von Salm
Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm.
By Taren Grom • March 29, 2023 -
SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi
The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market.
By Michael Gibney • March 28, 2023 -
How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work
Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.
By Alexandra Pecci • March 27, 2023 -
Cutting the cord — why streaming is a new frontier for pharma advertising
As streaming services proliferate, and more TV watchers buy in, there’s a new world of possibilities for DTC pharma marketing.
By Karissa Waddick • March 27, 2023 -
Sponsored by ProtaGene
Biosimilars Market Poised for an Exciting Future
As the biologics industry approaches its next patent cliff, what is the state of the biosimilars market?
March 27, 2023 -
Opinion
What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials
How life science execs would transform clinical trials with a little hocus pocus.
By PharmaVoice staff • March 24, 2023 -
Everyone says they’re patient-centric, but have they really walked the walk?
Life science leaders provide practical tips on how to create a sustainable patient-focused culture.
By Karissa Waddick • March 23, 2023 -
Podcast
Woman of the Week: RIGImmune’s Susan Sobolov
RIGImmune’s president is setting her sights on an off-the-shelf viral vaccine.
By Taren Grom • March 22, 2023 -
Making the leap from the lab to the boardroom
Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.
By Alexandra Pecci • March 21, 2023 -
SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape
Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.
By Michael Gibney • March 21, 2023 -
Biotech Spotlight
This biotech’s ‘Microsoft’ approach could change how we see gene therapy
The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.
By Karissa Waddick • March 20, 2023 -
‘The Last of Us’ might be fiction, but fungi are a looming threat
Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.
By Kelly Bilodeau • March 20, 2023 -
A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize
Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.
By Taren Grom • March 17, 2023 -
Making Moves
In the fallout from Aduhelm, Biogen’s leadership shakeup continues
The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.
By Karissa Waddick • March 16, 2023 -
Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back
A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.
By Michael Gibney • March 16, 2023 -
Podcast
Woman of the Week: Novartis Gene Therapies’ Chris Fox
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...
By Taren Grom • March 15, 2023 -
Profile
The power of connections for a startup CEO
Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.
By Alexandra Pecci • March 14, 2023 -
Profile
A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch
To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.
By Michael Gibney • March 14, 2023 -
Biden doubles down on drug pricing in 2024 budget — but boosts R&D
The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.
By Karissa Waddick • March 13, 2023 -
Q&A
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
By Kelly Bilodeau • March 13, 2023